Clinical Research Directory
Browse clinical research sites, groups, and studies.
Strengthening HPV Immunization Through EPI Leveraged Delivery
Sponsor: International Vaccine Institute
Summary
This is a randomized observer-blind placebo-controlled proof-of-concept study with the aim to assess the safety and tolerability, and the immunogenicity of a bivalent HPV vaccine administered in healthy infants and toddlers (9- and 15-month-olds) comparing them to an immune-bridging population of 15-20-year-old unmarried females in an open label study in Ghana at the Dodowa Health Research Center.
Official title: A Randomized, Observer-Blind, Placebo-Controlled, Proof-of-Concept Study to Assess the Safety, Tolerability and Immunogenicity of a Bivalent Human Papillomavirus (HPV) Vaccine in 9 and 15 Month Old Infants and Toddlers, 2-5 Year Old Children and an Open Label Single Dose Study in Young Unmarried Females Aged 15-20 Years in Ghana
Key Details
Gender
All
Age Range
9 Months - 20 Years
Study Type
INTERVENTIONAL
Enrollment
115
Start Date
2026-01-16
Completion Date
2028-12-31
Last Updated
2026-01-30
Healthy Volunteers
Yes
Conditions
Interventions
HPV vaccine
0.5 mL HPV Vaccine Injection Intramuscular
Placebo
0.5 mL Placebo injection intramuscular
Measles and rubella Vaccine
Measles and rubella Vaccine according to EPI
Locations (1)
Dodowa Health Research Center
Accra, Ghana